title: [A resected case of advanced gastric cancer after treatment with low-dosage TS-1].
abstract: We report a case of advanced gastric cancer that responded well to low-dosage TS-1. A 72-year-old woman was diagnosed as having unresectable advanced gastric cancer with ascites and hydronephrosis in the right kidney. She was treated with chemotherapy using a low-dosage of TS-1 (80 mg/body/day) administered perorally for 4 weeks followed by a drug-free 2 weeks, in six-week cycles. However, she developed weight loss, appetite loss, and stomatitis. We therefore reduced the dosage of TS-1 from 80 mg/body/day to 60 mg/body/day. The ascites and hydronephrosis gradually improved during the following 3 months, whereupon she could undergo total gastrectomy. The postoperative findings showed no ascites and no peritoneal dissemination. The postoperative pathological findings showed that the cancer cells were localized to within the mucosa, and there were no cancer cells in the greater and lesser omentum. Three weeks after the operation, TS-1 was resumed at 60 mg/body/day. However, 3 months later,ascites and metastasis to the abdominal skin developed, and she died 9 months after the operation.
authors.affiliation: Dept. of Surgery, Kurume University School of Medicine.
authors.forename: Keiko
authors.initials: K
authors.lastname: Matono
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ogata
authors.forename: Kikuo
authors.initials: K
authors.lastname: Koufuji
authors.forename: Keishirou
authors.initials: K
authors.lastname: Aoyagi
authors.forename: Shojiro
authors.initials: S
authors.lastname: Yano
authors.forename: Motoshi
authors.initials: M
authors.lastname: Miyagi
authors.forename: Takuya
authors.initials: T
authors.lastname: Imaizumi
authors.forename: Jinryo
authors.initials: J
authors.lastname: Takeda
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008197:Lymph Node Excision; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013280:Stomatitis / Q000139:chemically induced; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid